Please login to the form below

Not currently logged in
Email:
Password:

Erleada

This page shows the latest Erleada news and features for those working in and with pharma, biotech and healthcare.

Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer

Janssen will not seek regulatory approval for Erleada plus Zytiga in prostate cancer

activity may derive ‘clinical benefit’ from the Erleada/Zytiga combination treatment, according to Janssen. ... In the EU, Erleada is approved for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic

Latest news

More from news
Approximately 6 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Erleada (apalutamide) is the first drug to be cleared on the strength of metastasis-free survival (MFS), a trial endpoint not used before in any FDA cancer drug approval. ... The median MFS for patients taking Erleada was 40.5 months compared to 16.2

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...